Oncology · Precision Cancer Testing

MyeloMap
52-gene Myeloid Malignancy Panel

Targeted genomic profiling for AML, MDS and related myeloid neoplasms.

Peripheral blood/Bone marrow
Sample Type
1 FFPE block or 10–15 slides
Samples
10–14 working days
Turnaround Time

MyeloMap at Nucleome Informatics

52-gene Myeloid Malignancy Panel

Why this Test Matters

Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.

Who Should Consider this Test

  • AML
  • MDS
  • Disease progression
  • Relapse

Applicable Cancer Types

AML, MDS, Myeloid neoplasms

What the test covers and delivers

What is Covered

  • 52 genes
  • SNVs
  • InDels
  • Risk biomarkers

Clinical Utility​

  • Treatment selection
  • Prognostic and predictive biomarkers
  • Clinical trial matching
  • Identification of actionable alterations
  • Comprehensive clinical interpretation

Technology

Targeted myeloid sequencing

Test specifications

ParameterDetails
Sample TypePeripheral blood/Bone marrow
Samples1 FFPE block or 10–15 slides
Turnaround Time10–14 working days
Report IncludesVariant interpretation, therapy associations, clinically actionable biomarkers
QualityHigh-depth NGS with rigorous QC
Talk to our team. Email info@nucleomeinfo.com or call +91 40 40114169 to discuss sample requirements and turnaround for MyeloMap.